Rigel Pharmaceuticals (RIGL)
(Real Time Quote from BATS)
$1.12 USD
+0.02 (1.82%)
Updated Apr 29, 2024 10:36 AM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RIGL 1.12 +0.02(1.82%)
Will RIGL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RIGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RIGL
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
RIGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?
Other News for RIGL
Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy
Piper Sandler Remains a Hold on Rigel (RIGL)
12 Health Care Stocks Moving In Monday's After-Market Session
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma